Cargando…

MELD-Sarcopenia is Better than ALBI and MELD Score in Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation

BACKGROUND: The albumin bilirubin (ALBI) score and model of end stage liver disease (MELD) are prognostic in patients with hepatocellular carcinoma (HCC). Aim was to compare MELD-sarcopenia to MELD and ALBI scores in patients with HCC awaiting liver transplantation. METHODS: patients with HCC (n=262...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsebaey, Ayman, Aliaa, Aliaa, Rashed, Hanaa Said, Elsabaawy, Maha Mohammad, Ragab, Amr, Aly, Rasha Abdelhafiz, Badran, Hanaa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607083/
https://www.ncbi.nlm.nih.gov/pubmed/34319020
http://dx.doi.org/10.31557/APJCP.2021.22.7.2005
_version_ 1784602483380715520
author Alsebaey, Ayman
Aliaa, Aliaa
Rashed, Hanaa Said
Elsabaawy, Maha Mohammad
Ragab, Amr
Aly, Rasha Abdelhafiz
Badran, Hanaa
author_facet Alsebaey, Ayman
Aliaa, Aliaa
Rashed, Hanaa Said
Elsabaawy, Maha Mohammad
Ragab, Amr
Aly, Rasha Abdelhafiz
Badran, Hanaa
author_sort Alsebaey, Ayman
collection PubMed
description BACKGROUND: The albumin bilirubin (ALBI) score and model of end stage liver disease (MELD) are prognostic in patients with hepatocellular carcinoma (HCC). Aim was to compare MELD-sarcopenia to MELD and ALBI scores in patients with HCC awaiting liver transplantation. METHODS: patients with HCC (n=262) were included and followed up for 12 months. Baseline MELD, ALBI and MELD-sarcopenia models were calculated. RESULTS: The average age was 59.61 ±8.09 years. Most patients were males (69.5%), CTP class A (55.7%) and BCLC stage B (54.2%). Hepatitis C virus was the main cause of liver cirrhosis in most patients (88.9%). The average MELD, MELD-sarcopenia and median ALBI score were 10.65 ±2.54, 15.11 ±6.22 and -2.12 (0.74) respectively. Sarcopenia patients had higher MELD, ALBI and MELD-sarcopenia values. Patients with sarcopenia had lower survival (10.09 months) than those without (11.72 months). The ALBI, MELD and MELD-sarcopenia were associated with mortality. ALBI had AUROC of 0.717 (95% CI: 0.659 - 0.771), MELD had AUROC of 0.656 (95% CI: 0.595 - 0.713) and MELD-sarcopenia had AUROC of 0.798 (95% CI: 0.744 - 0.845). The ALBI and MELD scores had comparable AUROC (p=0.081). The MELD-sarcopenia had superior AUROC than MELD (p=0.001) and ALBI (p=0.05). CONCLUSION: MELD-sarcopenia is better prognostic model than the ALBI and MELD scores in HCC patients awaiting liver transplantation.
format Online
Article
Text
id pubmed-8607083
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-86070832021-11-26 MELD-Sarcopenia is Better than ALBI and MELD Score in Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation Alsebaey, Ayman Aliaa, Aliaa Rashed, Hanaa Said Elsabaawy, Maha Mohammad Ragab, Amr Aly, Rasha Abdelhafiz Badran, Hanaa Asian Pac J Cancer Prev Research Article BACKGROUND: The albumin bilirubin (ALBI) score and model of end stage liver disease (MELD) are prognostic in patients with hepatocellular carcinoma (HCC). Aim was to compare MELD-sarcopenia to MELD and ALBI scores in patients with HCC awaiting liver transplantation. METHODS: patients with HCC (n=262) were included and followed up for 12 months. Baseline MELD, ALBI and MELD-sarcopenia models were calculated. RESULTS: The average age was 59.61 ±8.09 years. Most patients were males (69.5%), CTP class A (55.7%) and BCLC stage B (54.2%). Hepatitis C virus was the main cause of liver cirrhosis in most patients (88.9%). The average MELD, MELD-sarcopenia and median ALBI score were 10.65 ±2.54, 15.11 ±6.22 and -2.12 (0.74) respectively. Sarcopenia patients had higher MELD, ALBI and MELD-sarcopenia values. Patients with sarcopenia had lower survival (10.09 months) than those without (11.72 months). The ALBI, MELD and MELD-sarcopenia were associated with mortality. ALBI had AUROC of 0.717 (95% CI: 0.659 - 0.771), MELD had AUROC of 0.656 (95% CI: 0.595 - 0.713) and MELD-sarcopenia had AUROC of 0.798 (95% CI: 0.744 - 0.845). The ALBI and MELD scores had comparable AUROC (p=0.081). The MELD-sarcopenia had superior AUROC than MELD (p=0.001) and ALBI (p=0.05). CONCLUSION: MELD-sarcopenia is better prognostic model than the ALBI and MELD scores in HCC patients awaiting liver transplantation. West Asia Organization for Cancer Prevention 2021-07 /pmc/articles/PMC8607083/ /pubmed/34319020 http://dx.doi.org/10.31557/APJCP.2021.22.7.2005 Text en https://creativecommons.org/licenses/by/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Alsebaey, Ayman
Aliaa, Aliaa
Rashed, Hanaa Said
Elsabaawy, Maha Mohammad
Ragab, Amr
Aly, Rasha Abdelhafiz
Badran, Hanaa
MELD-Sarcopenia is Better than ALBI and MELD Score in Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation
title MELD-Sarcopenia is Better than ALBI and MELD Score in Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation
title_full MELD-Sarcopenia is Better than ALBI and MELD Score in Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation
title_fullStr MELD-Sarcopenia is Better than ALBI and MELD Score in Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation
title_full_unstemmed MELD-Sarcopenia is Better than ALBI and MELD Score in Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation
title_short MELD-Sarcopenia is Better than ALBI and MELD Score in Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation
title_sort meld-sarcopenia is better than albi and meld score in patients with hepatocellular carcinoma awaiting liver transplantation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607083/
https://www.ncbi.nlm.nih.gov/pubmed/34319020
http://dx.doi.org/10.31557/APJCP.2021.22.7.2005
work_keys_str_mv AT alsebaeyayman meldsarcopeniaisbetterthanalbiandmeldscoreinpatientswithhepatocellularcarcinomaawaitinglivertransplantation
AT aliaaaliaa meldsarcopeniaisbetterthanalbiandmeldscoreinpatientswithhepatocellularcarcinomaawaitinglivertransplantation
AT rashedhanaasaid meldsarcopeniaisbetterthanalbiandmeldscoreinpatientswithhepatocellularcarcinomaawaitinglivertransplantation
AT elsabaawymahamohammad meldsarcopeniaisbetterthanalbiandmeldscoreinpatientswithhepatocellularcarcinomaawaitinglivertransplantation
AT ragabamr meldsarcopeniaisbetterthanalbiandmeldscoreinpatientswithhepatocellularcarcinomaawaitinglivertransplantation
AT alyrashaabdelhafiz meldsarcopeniaisbetterthanalbiandmeldscoreinpatientswithhepatocellularcarcinomaawaitinglivertransplantation
AT badranhanaa meldsarcopeniaisbetterthanalbiandmeldscoreinpatientswithhepatocellularcarcinomaawaitinglivertransplantation